Wilson Sonsini Goodrich & Rosati has advised Whitehawk Therapeutics. Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company, has announced that it has entered into a securities...
Whitehawk Therapeutics Announces $87.5 Million Private Placement Financing
Gilead Sciences Acquires Arcellx in $7.8 Billion Deal
Wilson Sonsini Goodrich & Rosati has advised Arcellx on the transaction, and Ropes & Gray LLP has advised Gilead Sciences. Gilead Sciences (Nasdaq: GILD) has entered...
Iambic Raises Over $100 Million in Oversubscribed Financing Round
Wilson Sonsini Goodrich & Rosati has advised Iambic. Iambic, a clinical-stage life science and technology company, has announced the completion of an oversubscribed financing round, raising...
Galvanize Therapeutics Secures $100 Million in Series C Financing
Wilson Sonsini Goodrich & Rosati has advised Galvanize Therapeutics, Inc. Galvanize Therapeutics, Inc., a commercial-stage medical technology company focused on pioneering pulsed electric field (PEF) therapies...
SpyGlass Pharma Raises $75 Million Series D Financing Round
Wilson Sonsini Goodrich & Rosati advised SpyGlass on the transaction. SpyGlass Pharma announced the successful closing of a $75 million Series D financing round aimed at...
Aadi Bioscience’s $849 Million ADC Deal, $100 Million FYARRO Sale and $100 Million PIPE Financing
Wilson Sonsini Goodrich & Rosati, P.C. is serving as legal counsel to Aadi. McDermott Will & Emery LLP is serving as legal counsel to Kaken. Cooley...
Magenta Medical’s $105 Million Financing Round
Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction. Magenta Medical (Magenta) announced that it has raised $105 million in financing. The financing was...
LENZ Therapeutics’ $30 Million Private Placement Financing
Wilson Sonsini Goodrich & Rosati advised LENZ Therapeutics on the transaction. LENZ Therapeutics (Nasdaq: LENZ), a late clinical-stage biopharmaceutical company, announced that it has entered into...
Iambic Therapeutics’ $50 Million Series B Extension Financing
Wilson Sonsini Goodrich & Rosati advised Iambic Therapeutics on the transaction. Iambic Therapeutics (Iambic), a clinical-stage biotechnology company, announced the closing of an oversubscribed $50 million...
LENZ Therapeutics’ Merger with Graphite Bio
Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
MapLight Therapeutics’ $225 Million Series C Funding Round
Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction. MapLight Therapeutics announced a $225 million Series C financing co-led by Novo Holdings, 5AM Ventures, Cowen...
Iambic Therapeutics’ $100 Million Series B Financing Round
Wilson Sonsini Goodrich & Rosati advised Iambic on the transaction. Iambic Therapeutics announced the closing of an oversubscribed $100 million Series B financing. The round was co-led by...